PRESS RELEASES

Date	Title
Feb 12, 2018	Ardelyx Announces Departure of Chief Scientific Officer
Feb 8, 2018	Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference
Jan 3, 2018	Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference
Jan 3, 2018	Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C
Dec 11, 2017	Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China
Nov 28, 2017	Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
Nov 21, 2017	Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline
Nov 7, 2017	Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress
Oct 16, 2017	Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
Oct 11, 2017	Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Boston Area
200 West Street, 4th Floor
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com